BACKGROUND: Severe acute muscle injury results in massive cell damage, causing the release of actin into extracellular fluids where it complexes with the vitamin D-binding protein (DBP). We hypothesized that a systemic DBP deficiency would result in a less proinflammatory phenotype.
T issue destruction and cell death lead to the release of previously sequestered intracellular molecules into extracellular fluids. 1 Several intracellular molecules (e.g., HMGB1, ATP, mitochondrial DNA) released into the extracellular environment as a result of cell damage have been shown to function as "alarmins" to signal the immune system to the presence of tissue injury.
2, 3 Alarmins induce recruitment and activation of innate immune cells resulting in the generation of proinflammatory cytokines. [2] [3] [4] In addition to alarmins, large quantities of actin are released into extracellular fluids whereby the protein escapes normal intracellular regulatory mechanisms and spontaneously forms F-actin filaments. In animal models, extracellular F-actin filaments have been shown to trigger angiopathic effects in the microcirculation, resulting in small vessel occlusion and promotion of disseminated intravascular coagulation. 5, 6 Accordingly, higher organisms have evolved an effective extracellular actin-scavenging system to remove actin released from dead or damaged cells. It is composed of two plasma proteins: gelsolin, a protein that severs F-actin into G-actin monomers, and vitamin D-binding protein (DBP) that tightly binds G-actin in a 1:1 complex and transports it primarily to the liver for clearance. 6, 7 Vitamin D-binding protein, also known as Gc-globulin or Gc-protein, is a plasma protein that is part of the albumin gene family and is the primary transport molecule for vitamin D sterols in the blood and extracellular fluids. 8, 9 Vitamin D-binding protein is synthesized by hepatocytes and circulates at 5 μM to 8 μM (300-450 μg/mL) concentration with a relatively rapid turnover in blood. 10 This protein is ubiquitous in vivo, and significant quantities (0.5-2 μM range) have been detected in nearly all extracellular fluid compartments. 10, 11 The plasma concentration of DBP is generally stable, even during an inflammatory acute phase reaction. 8 Several studies have demonstrated that in human sepsis, multiple trauma, and acetaminopheninduced liver failure, substantially reduced actin-free DBP levels correlate with poor prognosis. 6, [12] [13] [14] The decrease in plasma DBP is thought to result from injury-induced consumption, that is, formation of DBP-actin complexes that were rapidly cleared. Moreover, decreased plasma levels of DBP have a statistical prognostication capability comparable to the Acute Physiology and Chronic Health Evaluation II score, Trauma Revised Injury Severity Score, or King's College criteria in sepsis, trauma, or liver failure, respectively. 6, 12, 13 It has been speculated that the primary physiological role of DBP is as a scavenger of extracellular actin because it binds to actin with high affinity (K d of 10 −9 M), and a large fraction of total circulating DBP (>50%) can be bound to actin following extensive tissue injury. 5, 6 It is not clear whether DBP functions primarily as a rapid clearance mechanism for actin, or whether DBP-actin complexes are bioactive. [15] [16] [17] We hypothesize that a systemic deficiency of DBP would result in a less proinflammatory phenotype; the presence of free actin would not result in the above listed adverse effects of free actin. To this end, we investigated the role of DBP in a muscle injury model using mice with a systemic deficiency in DBP and their wild-type (WT) DBP sufficient counterparts. This model was selected because skeletal muscle contains the largest amount of actin of any tissue, and consequently, it is presumed that injury would generate large amounts of DBP-actin in WT mice but no complexes in DBPdeficient mice.
METHODS

Animals
Mice with a systemic deficiency in DBP (DBP−/−) are currently housed at Stony Brook University, the only worldwide source of the DBP−/− mouse strain, which has been fully backcrossed on a WT C57BL/6J background for 12 generations. 17 The deletion of the DBP gene has been verified by genotyping (Transnetyx, Cordova, TN) and by immunoblotting of DBP−/− plasma. Wild-type DBP+/+ mice were either bred at Stony Brook or obtained from Jackson Labs (Bar Harbor, ME). Mice were housed in a maximum isolation facility, and all experiments used 8-week-to 12-week-old mice with equal numbers of males and females. Animal experiments were performed using protocols approved by the Institutional Animal Care and Use Committee at our university.
Acute Muscle Injury Model
Briefly, 5 mL/kg (125 μL for a 25-g mouse) of sterile 50% glycerol (99.9% pure; Acros Organics, Morris Plains, NJ) was injected along the length of the left thigh muscles of anesthetized mice, as previously described. 18, 19 Control mice were injected with 125 μL of sterile phosphate-buffered saline (PBS) along the length of the right thigh muscles to serve as the shamtreated group. Different injection sites were used for glycerol versus PBS as a procedural check to verify that mice were either in the sham or experimental groups. There were four treatment groups (two mouse strains Â two treatments) that were analyzed 48 hours after treatment to evaluate the start of the postinjury recovery phase. The glycerol-treated group contained eight animals per group, whereas the PBS-injected sham controls had six mice per group. The number of mice was chosen based on a power calculation in consultation with our biostatistical core, which indicated that we needed at least six mice per group to have a power of 0.8 (ie, an 80% chance to correctly determine a 10% difference between treatments at p < 0.05). Blood (EDTA plasma), thigh muscles from the injected extremity, kidneys, and lungs were collected 48 hours after injection and immediately frozen at −80°C; samples were thawed and refrozen no more than twice.
Tissue Homogenization Procedure
Frozen tubes containing skeletal muscle, kidneys, or lungs were placed in a 37°C water bath for rapid thawing, followed by placing samples on ice. All procedures used sterile instruments and plasticware in a BSL-2 laminar flow hood. Each tissue was dissected to remove fat and/or connective tissue, cut into small pieces, and then added to a sterile 5-mL round-bottom tube containing homogenization buffer at a ratio of 0.5 mL/100 mg tissue. Homogenization buffer consisted of PBS, 50 mM Tris-HCl (pH 7.5), 2.5 mM EDTA, 0.5% Triton X-100 with a complete protease inhibitor cocktail (1 mM Pefabloc SC, 0.125 mM E-64, and one Complete mini protease inhibitor tablet; all reagents were purchased from Roche Life Sciences, Indianapolis, IN). Tissue was homogenized on ice using a handheld electric tissue grinder until it was completely liquefied. The homogenized tissue was next centrifuged at 15,000g at 4°C for 10 minutes in a microfuge, and the supernatant transferred to a new sterile tube. An aliquot was removed from each sample for analysis of total protein using the Bradford protein assay kit (BioRad, Hercules, CA). Samples were then frozen at −80°C both as aliquots from individual mice and pooled samples from each treatment.
Cytokine Analysis
Cytokine levels in total pooled plasma and organ tissue homogenates from each group were first determined by a multiplex enzyme-linked immunosorbent assay (ELISA) (eBiosciencesAffymetrix/Thermo Fisher, Waltham, MA) analyzing 36 cytokines per sample. Data were analyzed using a BioPlex Luminex plate reader (BioRad) in our Genomics core facility. Pooled samples were used as a cost-effective approach to identify to systemic cytokine changes. [20] [21] [22] This method of screening 36 cytokines allowed us to identify the molecules that differed between WT and DBP-deficient animals and subsequently to customize a multiplex ELISA (eBiosciences-Affymetrix/Thermo Fisher) for analyzing 12 key cytokines: CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CXCL1 (GRO-α), CXCL2 (MIP-2), CXCL5 (ENA-78), CXCL10 (IP-10), granulocyte colony-stimulating factor (G-CSF) (CSF-3), interleukin 2 (IL-2), IL-6, and IL-10. These cytokines were measured in samples from both individual mice and three different pools in each of the four experimental groups. To ensure the validity of the data, each sample was measured three times: 36-plex of pooled samples as a screen, 12-plex of individual samples, 12-plex of three different pools. Results reported herein are those from a 12-plex of individual samples or pooled samples.
Histology
Organ tissue was evaluated for histological evidence of inflammation and tissue injury in separate groups of mice 48 hours after glycerol or PBS injection, n = 3 mice per group. At the time of dissection, thigh muscle, kidneys, and lungs were immersed in 10% neutral buffer formalin for 24 hours and then processed in the Histology Core Lab where hematoxylin-eosin (H&E)-stained slides were prepared. The H&E-stained sections were coded to conceal both the mouse strain and treatment. For the slides of skeletal muscle, the entire tissue section was evaluated by a board-certified pathologist for the degree of inflammation and myonecrosis using a 0-point to 4-point semiquantitative grading scale. The degree of tissue inflammation was scored as follows: no inflammation = 0, minimal = 1, mild = 2, moderate = 3, or severe inflammation = 4. Muscle necrosis was scored as no necrosis = 0, 1% to 5% = 1, greater than 5% to 10% = 2, greater than 10% to 25% = 3, or greater than 25% = 4. In a separate analysis, the type of inflammatory cell infiltrate in muscle was quantitated by examining three nonoverlapping high-power (400Â) fields. Only the H&E slides from glycerol-treated mice were quantitated because PBS-treated mice did not have adequate numbers of inflammatory cells for accurate statistical analysis. The percent neutrophils (identified by size, nuclear morphology, and staining pattern) in 200 total inflammatory cells in each of three 400Â fields were counted. The data are presented as the mean percent PMN (neutrophils) and MNC (mononuclear cells) of 600 cells counted.
Analysis of DBP and DBP-Actin Complexes in Plasma
Pooled plasma samples from each experimental group (n = 6 for PBS groups, n = 8 for glycerol-treated groups) were separated by polyacrylamide electrophoresis under nondenaturing conditions (no sodium dodecyl sulfate) to preserve DBP-actin complexes. All pooled plasma samples in the four experimental groups had similar total protein levels (±5%), and the same amount of protein was loaded in each lane. Plasma samples were first diluted 1:1 with nondenaturing sample buffer (50 mM Tris-HCl, pH 6.8, 20% glycerol, 0.1% bromophenol blue tracking dye) and then separated on a 10% native polyacrylamide gel (BioRad) followed by blotting onto a PVDF membrane (Millipore, Bedford, MA). The membrane was probed for immunoreactive DBP using an affinity-purified polyclonal goat anti-human DBP (purchased from DiaSorin and subsequently affinity purified in our laboratory) followed by horseradish peroxidase-conjugated donkey anti-goat immunoglobulin G (Santa Cruz Biotechnology, Santa Cruz, CA) as the secondary antibody. (Note: DBP is highly conserved in mammals, and mouse DBP strongly cross reacts with anti-human DBP.) The blot was developed using BioRad ECL reagents and imager. In a separate experiment to validate DBP-actin complex formation in mouse plasma, WT C57BL/6J mouse plasma pooled from untreated mice (n = 3) was spiked in vitro with various amounts of purified G-actin (Cytoskeleton, Denver, CO) for 30 minutes at 22°C and then subjected to nondenaturing polyacrylamide electrophoresis and immunoblotting as above. These samples served as a positive control for the position of DBP and DBPactin bands on the immunoblot. The relative percent difference between DBP band intensity in PBS versus glycerol-treated mouse plasma was estimated by measuring the band pixel density using Adobe Photoshop software (Adobe Systems, San Jose, CA).
Data Analysis and Statistics
Statistical analysis and graphing of quantitative data were performed using GraphPad Prism software version 7.0c (La Jolla, CA). All multiplex ELISAvalues from tissues homogenates were normalized per milligram total tissue protein (pg/mg). Data were analyzed for statistical differences between WT and DBP−/− (ie, DBP KO) mice for each treatment (glycerol or PBS) using an unpaired t test with the Holm-Sidak correction method. This study was designed to evaluate the difference between the strains (WT versus DBP KO) and not between the treatments (PBS vs. glycerol), because it was presumed that the glycerol treatment would produce significant injury and inflammation (according to multiple prior publications). Therefore, the Student t test was used to evaluate differences between the mouse strains. Nevertheless, data were also evaluated using a two-way analysis of variance with Tukey multiple-comparisons method, which showed that statistical differences were maintained, but the level of significance was not as great as with the t test.
RESULTS
Thigh muscle at the site of glycerol-induced injury demonstrated no morphological difference in tissue damage between DBP-deficient (DBP−/−) and WT (DBP+/+) mice (Fig. 1) . Both strains of mice showed extensive myonecrosis and inflammatory infiltrate 48 hours after glycerol injection that was not observed in the PBS-injected sham control groups. Semiquantitative histopathology scores confirmed that the glycerol injection induced significant necrosis of skeletal myocytes and inflammation (Fig. 2, A and B) . Moreover, following glycerol injection, WT animals had a mixed neutrophil (37%) and mononuclear cell (63%) infiltrate, whereas DBP-deficient mice had an almost exclusive mononuclear cell response (95%) with very few neutrophils (Fig. 2C) . Analysis of the H&E-stained sections of kidney and lung tissue by light microscopy showed no evidence of tissue injury in either WT or DBP-deficient mice (data not shown). Analysis of 36 cytokines in pooled samples allowed us to customize a multiplex ELISA to measure 12 key cytokines previously mentioned. We subsequently evaluated these cytokine levels in samples from individual animals (plasma, muscle, kidney) or in pooled samples (lung) from WT mice and DBP−/− (KO) mice 48 hours after intramuscular injection of glycerol or PBS. Intramuscular glycerol injection induced a marked systemic inflammatory response in WT mice, as evidenced by a significant increase in plasma IL-6 levels (Fig. 3A) . However, the amount of plasma IL-6 in DBP KO mice was significantly lower than that in WT animals (Fig. 3A) . Furthermore, as described above, a significant decrease in neutrophil infiltrates in muscle was noted in glycerol-damaged muscle in DBP−/− mice (Fig. 2C) . Hence, we examined two additional cytokines that are involved in neutrophil development (G-CSF) and tissue recruitment/homeostasis (CXCL5) (Fig. 3, B and C) . Plasma levels of CXCL5 and G-CSF are both decreased in DBP-deficient mice versus their WT counterparts, perhaps providing a partial explanation of why DBP KO mice had significantly fewer neutrophils recruited to the glycerol-damaged muscle. No differences were observed between WT and KO mice in plasma levels of CCL3, CCL4, and CXCL10 following glycerol administration. Interleukin 2 was not detected in any sample.
Glycerol-induced muscle injury in WT mice resulted in increased levels of CCL2 (a monocyte chemoattractant) and CXCL1 (a neutrophil chemoattractant), in plasma, muscle, kidney, and lung (Figs. 4 and 5 ). CCL2 levels in kidney and lung were significantly lower in DBP KO mice than in WT mice, whereas plasma CCL2 levels just failed to reach statistically significant difference (p = 0.056, Fig. 4) . Meanwhile, CXCL1 levels were significantly reduced in DBP KO mice as compared with WT mice following glycerol-induced muscle injury in all tissues examined (Fig. 5 ). These results demonstrate that, as compared with WT mice, DBP-deficient mice produce significantly less quantities of two major inducible chemoattractants (CCL2, CXCL1) after tissue injury.
As kidney damage is a serious consequence of acute muscle injury, we further analyzed kidney homogenates following glycerol administration. Besides the significant decreases in CCL2 and CXCL1 levels in DBP KO mice, kidney homogenates from glycerol-injected DBP−/− mice also had significantly lower levels of the chemokines CXCL2 and CCL5 versus WT mice (Fig. 6 ). Interleukin 10 was significantly elevated in sham-treated WT mice versus DBP-deficient animals, and these levels decreased with glycerol-induced injury but only in WT mice (Fig. 6) . Thus, kidney homogenates from DBP KO mice have significantly diminished levels of these proinflammatory cytokine as compared with their WT counterparts.
DISCUSSION
To investigate the role of DBP in acute muscle injury, a glycerol-induced acute muscle injury model was utilized. This model, as opposed to a femur fracture model, for example, was selected because skeletal muscle has the largest amount of actin of any tissue, and injured muscle fibers will release these very large quantities of actin. To our knowledge, this is the first report of a possible role of the effects of DBP deficiency on systemic and tissue cytokines levels following acute muscle injury.
A complete systemic deficiency of DBP is the only known difference between DBP-deficient and WT C57BL/6J mice; these mice are otherwise phenotypically normal. 17 Previous experiments have shown that WT DBP+/+ complement-activated serum instilled into the lungs of DBP−/− mice can restore their diminished influx of neutrophils into the airspaces, 17 suggesting that repletion of DBP in these deficient mice can reverse the neutrophil recruitment defect. We hypothesized that this effect of DBP is mediated through either the actin or vitamin D-binding functions, and because actin binding is immediate and observed during tissue injury, we focused on DBP-actin complexes. Indeed, 48 hours after acute muscle injury, an entirely different systemic cytokine profile, favoring an anti-inflammatory/reparative phenotype, is generated in DBP-deficient mice compared with their WT counterparts. This correlates with the reduced neutrophilic infiltrate in muscle.
Our acute muscle injury model demonstrated extensive myonecrosis and inflammation in the thigh muscles of all mice injected with 50% glycerol. Moreover, glycerol treatment of WT mice also resulted in a 65% reduction in total plasma DBP, perhaps reflecting injury-induced consumption, which obviously was not seen in DBP-deficient animals. However, except for CXCL1, there was no difference between WT and DBPdeficient mice in muscle cytokine levels. Nevertheless, the cell composition of the inflammatory infiltrates was significantly different. It remains to be determined why there were significant differences between several systemic, kidney, and lung cytokines but little difference at the site of tissue injury. One possible explanation is that the dose of glycerol used for this model induces mild muscle injury as compared with several other agents such as toxins (cardiotoxin, notexin), chemicals (barium chloride), or freeze injury that produce more extensive damage that peaks 4 days to 6 days after injury. 19, 23 In contrast to the limited local cytokine effects at the site of muscle injury, significant changes in cytokine levels after glycerol-induced injury were observed in the plasma, lung, and particularly the kidneys of WT mice. Kidney damage is an important consequence of severe muscle injury. 24, 25 The glycerolinduced muscle injury model can also induce acute renal failure at twice the glycerol concentration used herein when coupled with water deprivation. 26 Although kidneys from WT mice had elevated levels of several chemokines (CCL2, CCL5, CXCL1, CXCL2) versus DBP-deficient animals, evidence of kidney damage by light microscopy was not observed, as expected. Injury to glomeruli and tubules is often subtle and usually requires examination via electron microscopy to reveal damage.
An interesting finding in this study is that DBP−/−mice had almost no neutrophils at site of muscle injury. These data indicate that a systemic deficiency of DBP results in a reduction in neutrophilic inflammation. Perhaps this is partly mediated by decreased levels of several neutrophil chemoattractants in plasma (i.e., CXCL1, CXCL2, CXCL5, and G-CSF). Significantly reduced levels of the chemokines CCL2 and CXCL1 in almost all harvested tissues from DBP-deficient mice were a key finding in this study. CXCL1 (GRO-α) is a major inducible chemoattractant, generated during inflammation that contributes to neutrophilic tissue infiltrates. 27 Indeed, CXCL1 is the mouse homolog of human IL-8 (CXCL8) and has very similar functions and disease associations as IL-8.
28 CCL2 (MCP-1) is also a major inducible chemoattractant; it contributes to monocytic tissue infiltrates. 24 In addition to reduced CXCL1 and CCL2 levels, DBP-deficient mice also had significantly decreased levels, in other cytokines that induce neutrophil development in the bone marrow (G-CSF), mobilization from the bone marrow to the blood (CXCL2), and recruitment from blood into tissue (CXCL5). [29] [30] [31] These cytokine results are consistent with our previously published studies investigating the effects of DBP in acute and chronic lung injury, where DBP-deficient mice had significantly fewer neutrophils in lung parenchyma and bronchoalveolar fluid after injury. Moreover, in these prior studies, the diminished neutrophilic inflammation correlated with less tissue injury and better survival. 16, 17 Lung tissue was also examined because lungs are a prime target of systemic injury and also a key organ for systemic neutrophil regulation. 32 Indeed, DBP−/− mice had significantly lower levels of CCL2 and CXCL1 in lung homogenates. There are several limitations to the current study. First, this work was performed using inbred mice housed in an aseptic maximum isolation room, so potential extrapolation of these results to traumatic muscle injury in humans would be debatable and premature. Second, the experimental approach in this study examined tissues only at a single time point (48 hours) after acute muscle injury and consequently does not address the very dynamic spectrum of cellular and molecular changes that occur during the process of host response to tissue injury.
CONCLUSIONS
The results from this study clearly demonstrate that DBPdeficient mice had significantly lower amounts of several tissue and plasma cytokines following acute muscle injury, suggesting that DBP deficiency may play an as yet unrecognized role in traumatic injury. As DBP deficiency exposes tissues to large quantities of free actin, our findings refute the concept that free actin is proinflammatory. It is possible that DBP deficiency, and consequently the inability to generate DBP-actin complexes, is the principal reason that DBP KO mice have a less proinflammatory phenotype. The experiments reported herein, coupled with our previously published studies using DBP-deficient mice, suggest that DBP deficiency would preclude the generation of DBPactin complexes; these complexes may have alarmin-like functions and are thereby proinflammatory. 16, 17 However, at present, there is no direct method to quantitate the rapidly cleared DBPactin complexes in biological fluids. Additional study is needed to understand the role of DBP deficiency and consequently the absence of DBP-actin complexes in the host response to tissue injury. Vitamin D-binding protein and actin are ubiquitous proteins that are ideal candidates to act as rapid sentinels of tissue injury. AUTHORSHIP R.R.K. designed the study and performed experiments, data analysis and interpretation, and manuscript preparation. T.T. performed experiments and data analysis and interpretation. J.E.D. performed data analysis and interpretation. J.A.V. designed the study and performed critical revision of the manuscript. R.S.J. designed the study and performed experiments, data analysis and interpretation, and manuscript preparation.
How did you know that there are actin-DBP complexes in this actual experiment? I know your previous work showed actin-DBP complexes but were there actin-DBP complexes as a result of this injury? Were you able to isolate any of those complexes?
My final question is can you reproduce the findings in the reverse direction? Meaning, can you either inject complexes into healthy mice or can you block the binding site of actin on the DBP protein in wild-type mice and show the same effect?
I want to thank the authors for their presentation and thank the AAST for the opportunity to discuss this paper.
Dr. Carl. J. Hauser (Boston, Massachusetts): This is very nice work. I applaud it and I applaud your getting the model past your IACUC since it's very difficult to get this kind of model of tissue necrosis past them, at least in my institution.
I'd like to offer another explanation for the lack of neutrophil infiltration into tissues here which is that the release of any intracellular contents can be a marker for release of other kinds of damage molecules, especially formyl peptides. Engaging formyl peptide receptors on phagocytes will heterologously suppress receptors for chemokines (CXCR1/R2), for leukotrienes (BLT1/2) and for essentially all other chemoattractant agents. So you may be looking here at a diffuse innate-immunosuppressive phenomena.
So like the prior speaker I encourage you to actually reverse the experiment and give the molecules of interest and see whether they are readouts for effect or collateral markers for effect. Either way, they are very good biomarkers and this is very nice work.
Dr. Randeep S. Jawa (Stony Brook, New York): So, I'd like to thank the discussants for their comments.
With regards to the initial question as to whether freeactin is an anti-inflammatory agent, our previous work has shown that when we injected IV actin it created a significant systemic inflammatory response, characterized by significant lung damage. So it's probably not anti-inflammatory.
With regards to there being significantly less neutrophils in the areas of initial injury and how do we know that these mice are not immunosuppressed, the basic answer to this is these mice are phenotypically normal no matter which way we have tested them. That's actually the straightest answer I have for that.
How did you know that the actin-DBP complexes were actually formed in these mice and were you able to isolate these complexes? So there is no direct way to actually measure DBP actin complexes.This is an indirect measurement that I showed on the study from Ge. So the answer to your question is we have not done it with this specific experiment. But that's something that we are planning on doing as the next part of this experiment.
In terms of can you reproduce these findings in the reverse direction, these have been reproduced with regards to actin injection.When mice that were deficient in DBP, received actin, they had an attenuated inflammatory response. However, once the DBP was re-injected into them, the inflammatory response was similar.
With regards to Dr. Hauser's question, it's the same thing. I would agree with your comments. And one of the steps that we had originally proposed was DBP reinjection back into the tail-vein of KO mice in this muscle injury model. Thank you.
